Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Doi et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01897-20
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Small RCT comparing late and very late (7 and 14 days from fever onset) favipiravir. Viral clearance was non-statistically significantly improved with relatively early treatment. There was a reduction in time to defervescence, and a significant improvement in fever was observed the day after starting therapy. There was no progression or mortality. While limited by the small sample size, authors conclude that the results suggest antiviral activity of favipiravir in this patient population. There was no control group.
Doi et al., 17 Nov 2020, Randomized Controlled Trial, peer-reviewed, 45 authors.
This PaperFavipiravirAll
Abstract: ANTIVIRAL AGENTS crossm A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 Yohei Doi,a,b Masaya Hibino,c Ryota Hase,a,d Michiko Yamamoto,e Yu Kasamatsu,f Masahiro Hirose,g Yoshikazu Mutoh,h Yoshito Homma,i Masaki Terada,j Taku Ogawa,k Fumihiro Kashizaki,l Toshihiko Yokoyama,m Hayato Koba,n Hideki Kasahara,o Kazuhisa Yokota,p Hideaki Kato,q Junichi Yoshida,r Toshiyuki Kita,s Yasuyuki Kato,t Tadashi Kamio,u Nobuhiro Kodama,v Yujiro Uchida,w Nobuhiro Ikeda,x Masahiro Shinoda,y Atsushi Nakagawa,z Hiroki Nakatsumi,aa Tomoya Horiguchi,bb Mitsunaga Iwata,c Akifumi Matsuyama,cc Sumi Banno,dd Takenao Koseki,dd,ee Mayumi Teramachi,dd Masami Miyata,dd Shigeru Tajima,ff Takahiro Maeki,ff Eri Nakayama,ff Satoshi Taniguchi,ff Chang Kweng Lim,ff Masayuki Saijo,ff Takumi Imai,gg Hisako Yoshida,gg Daijiro Kabata,gg Ayumi Shintani,gg Yukio Yuzawa,hh Masashi Kondobb,dd a Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan b Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA c Department of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan d Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan e Department of Respiratory Medicine, Sagamihara Kyodo Hospital, Sagamihara, Kanagawa, Japan f Infection Control and Clinical Laboratory, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan g Department of Respiratory Medicine, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan h Department of Infectious Diseases, Tosei General Hospital, Seto, Aichi, Japan i Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan j Department of Respiratory Medicine, Saiseikai Niigata Hospital, Niigata, Niigata, Japan k Center for Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan l Department of Respiratory Medicine, Isehara Kyodo Hospital, Isehara, Kanagawa, Japan m Department of Respiratory Medicine, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan n o Department of Rheumatology, NTT East Sapporo Hospital, Sapporo, Hokkaido, Japan p Department of Infectious Diseases, Tokyo Metropolitan Health and Medical Corporation Ebara Hospital, Ohta, Tokyo, Japan q Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Kanagawa, Japan r Department of Chest Surgery, Shimonoseki City Hospital, Shimonoseki, Yamaguchi, Japan s Department of Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan t Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan u Department of Intensive Care, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan v Department of General Internal Medicine, Fukuoka Tokushukai Hospital, Kasuga, Fukuoka, Japan w Department of General Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan x Department of General Internal Medicine, Eiju General Hospital, Taito, Tokyo, Japan y Department of Respiratory Medicine, Tokyo Shinagawa Hospital, Shinagawa, Tokyo, Japan z Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan aa Department of..
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit